What the FDA labels say about taking them together
Dexlansoprazole and nilotinib
Dexlansoprazole's FDA label of February 17, 2025 names nilotinib in its drug interactions section; nilotinib's label does not name dexlansoprazole itself but warns about its class (Proton pump inhibitors (PPIs)). The dexlansoprazole label: “Dexlansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.”
Check it at the source: the dexlansoprazole FDA label on DailyMed (effective February 17, 2025, Takeda Pharmaceuticals America, Inc.); the nilotinib FDA label on DailyMed (effective December 16, 2025, Novartis Pharmaceuticals Corporation).
What does the dexlansoprazole label say about nilotinib?
Dexlansoprazole label, drug interactionsClinical Impact: Dexlansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. Intervention: Mycophenolate mofetil (MMF): Coadministration of PPIs in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH. …
Source: FDA drug label (Dexilant), Takeda Pharmaceuticals America, Inc., effective February 17, 2025 (SPL set 9819f033-3bbe-442e-8e92-45fec77b237d), via openFDA; the full label on DailyMed
What does the nilotinib label say about dexlansoprazole?
Nilotinib's label does not name dexlansoprazole itself; it warns about its class (Proton pump inhibitors (PPIs)):
Nilotinib label, drug interactionsAvoid concomitant use with Tasigna. Use short-acting antacids or H2 blockers as an alternative to proton pump inhibitors.
Nilotinib label, drug interactionsProton Pump Inhibitors Concomitant use with a proton pump inhibitor (PPI) decreased nilotinib concentrations compared to Tasigna alone [see Clinical Pharmacology (12.3)], which may reduce Tasigna efficacy.
Source: FDA drug label (Tasigna), Novartis Pharmaceuticals Corporation, effective December 16, 2025 (SPL set 6093952a-5248-45cb-ad17-33716a411146), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Dexlansoprazole | Nilotinib | |
|---|---|---|
| Labeled for | Acid reflux and ulcers | Leukemia, lymphoma and myeloma |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $3.71 per capsule 60 mg capsule | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once